<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01059734</url>
  </required_header>
  <id_info>
    <org_study_id>S9031-S9126-S9333-S9500-B</org_study_id>
    <secondary_id>S9031-S9126-S9333-S9500-B</secondary_id>
    <secondary_id>U10CA032102</secondary_id>
    <nct_id>NCT01059734</nct_id>
  </id_info>
  <brief_title>S9031-S9126-S9333-S9500-B Biomarker Expression in Patients With Acute Myeloid Leukemia</brief_title>
  <official_title>Topoisomerase 2 Expression and Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of bone marrow from patients with cancer in the laboratory may
      help doctors learn more about changes that occur in DNA and identify biomarkers related to
      cancer.

      PURPOSE: This research study is looking at biomarker expression in bone marrow samples from
      patients with acute myeloid leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Estimate the distributions of topoisomerase 2 (TOP2) expression and single nucleotide
           polymorphisms (SNPs) in patients with newly diagnosed acute myeloid leukemia (AML).

        -  Estimate the distributions of mutations in TOP2 phosphorylation sites (by SNP analysis)
           in these patients.

        -  Investigate whether expression of TOP2 or mutations in TOP2 phosphorylation sites vary
           with patient or disease characteristics in these patients.

        -  Test whether TOP2 expression correlates with complete remission rates, relapse-free
           survival, and overall survival of these patients.

        -  Conduct preliminary analyses to estimate the distributions of TOP2 expression and
           mutations in TOP2 phosphorylation sites (by SNP analysis) in patients with relapsed
           and/or refractory AML.

        -  Investigate whether expression of TOP2 and mutations in TOP2 phosphorylation sites vary
           with patient or disease characteristics in patients with relapsed and/or refractory AML.

        -  Test whether TOP2 expression and mutations in TOP2 phosphorylation sites differ between
           previously untreated and relapsed/refractory AML patients.

      OUTLINE: This is a multicenter study.

      Archived RNA specimens are analyzed for topoisomerase 2 transcriptional expression by
      quantitative real-time polymerase chain reaction (PCR) and for mutations within TOP2
      phosphorylation sites by single nucleotide polymorphism analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Distribution of topoisomerase 2 (TOP2) expression and single nucleotide polymorphisms</measure>
    <time_frame>immediate</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distributions of mutations in TOP2 phosphorylation sites</measure>
    <time_frame>immediate</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of TOP2 expression with complete remission rates, relapse-free survival, and overall survival</measure>
    <time_frame>immediate</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation of TOP2 expression and mutations in TOP2 phosphorylation sites among patients and disease characteristics</measure>
    <time_frame>immediate</time_frame>
  </primary_outcome>
  <enrollment type="Actual">357</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients enrolled on S0931, S9126, S9333 or S9500 consenting to use of specimens for future
        research
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of acute myeloid leukemia

               -  All subtypes allowed (except acute promyelocytic leukemia [M3])

               -  Previously untreated OR relapsed/refractory disease

          -  Isolated RNA specimens from bone marrow aspirate samples available from patients who
             participated on SWOG-9031, SWOG-9333 (cytarabine/daunorubicin hydrochloride induction
             arm only), SWOG-9500, or SWOG-9126

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anjali Advani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2010</study_first_submitted>
  <study_first_submitted_qc>January 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2010</study_first_posted>
  <last_update_submitted>March 5, 2015</last_update_submitted>
  <last_update_submitted_qc>March 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with del(5q)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>adult erythroleukemia (M6a)</keyword>
  <keyword>adult pure erythroid leukemia (M6b)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

